News Release

Suven Life Sciences to make two presentations at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting in Scottsdale, Arizona, USA.

Hyderabad, India (28-May-2025) - Suven Life Sciences, a clinical-stage biopharmaceutical company focused on central nervous system (CNS) disorders, today announced that it will give two presentations at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting, to be held in Scottsdale, Arizona, USA, from during 27–30, 2025.

The **ASCP Annual Meeting** is the premier meeting each year in the field of psychopharmacology, bringing together representatives from academia, the National Institutes of Health (NIH), Food and Drug Administration (FDA), European regulatory agencies, and industry to discuss key aspects of neuropsychiatric drug development, including the impact of diagnostic changes and personalized interventions based on biomarkers or genetic information.

The presentations will feature key updates from Suven's advancing pipeline of innovative treatments for neuropsychiatric disorders:

28-May-2025 (W85): *Non-Clinical Efficacy and Safety of SUVN-L3307032, a Muscarinic M4 Positive Allosteric Modulator (M4 PAM), for the Treatment of Neuropsychiatric Symptoms Associated with Schizophrenia and Alzheimer's Disease.*

29-May-2025 (T85): *Ropanicant (SUVN-911), an α4β2 nAChR antagonist: Outcome of a Phase-2a Clinical Trial Evaluating the Safety and Efficacy in Participants with Moderate to Severe Major Depressive Disorder.*

About Ropanicant (SUVN-911): Ropanicant is a novel, potent and selective α4β2 nAChR antagonist. It has excellent ADME properties like oral bioavailability and brain penetration, and does not have drug-drug interaction liability. Ropanicant has shown robust efficacy in various animal models of depression. The efficacy in animal models was in conjunction with an increase in serotonin levels in prefrontal cortex. It does not act like conventional SSRIs i.e., efficacy onset is faster than SSRIs (most likely acts by enhancing the release of monoamine neurotransmitters). Ropanicant addresses major limitations of current depressive disorder therapeutics by offering rapid onset of action, no sexual dysfunction. Additionally, it shows pro-cognitive effects. Pre-clinical in-vitro and in-vivo efficacy studies, supporting neurochemical studies, pharmacokinetic studies, safety studies and Phase-1 studies in healthy subjects under US IND have been successfully completed for Ropanicant.

About Ropanicant (SUVN-911) Phase-2a Clinical Study: The Phase-2a study evaluated the safety and efficacy of ropanicant in major depressive disorder patients (ClinicalTrials.gov Identifier: NCT06126497). The study randomized 41 patients in the ratio of 1:1:1 to Ropanicant 45 mg qd, Ropanicant 30 mg bid, or Ropanicant 45 mg bid treatment groups. Ropanicant effects on the depressive symptoms were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS) score. The total treatment duration was 14 days. The study was conducted in the USA.

About Suven Life Sciences: Suven Life Sciences Limited (Suven) is focused on the discovery and clinical development of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders. We have portfolio of advanced stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer's disease (AD), Sleep disorders, Major depressive disorders (MDD), Parkinson's disease (PD), Schizophrenia, Pain disorders, and Gastrointestinal disorders. Suven has 5 clinical stage assets across focus areas: Masupirdine (SUVN-502) for the treatment of agitation in patients with dementia of the Alzheimer's type (Phase-3 study ongoing); Samelisant (SUVN-G3031) for excessive daytime sleepiness (EDS) in narcolepsy (Phase-2 study for EDS completed; Phase-2 study for Cataplexy and pivotal Phase-3 study for EDS are in planning); Ropanicant (SUVN-911) for MDD (Open-label Phase-2a study completed; Placebo-controlled Phase-2b study initiated); Usmarapride (SUVN-D4010) for cognitive disorders (Phase-2 study in planning), SUVN-I6107 for cognitive disorders (Phase-1 study ongoing). In addition to these clinical assets, we have 7 projects in research pipeline across multiple potential indications. Suven owns all intellectual property rights for its assets in all major markets.

For more information, please visit our website http://www.suven.com

Risk Statement: *Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve several risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances, and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.*